Modulating anti-HIV immunity by plasmacytoid dendritic cells
通过浆细胞样树突状细胞调节抗 HIV 免疫
基本信息
- 批准号:8607497
- 负责人:
- 金额:$ 2.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-15 至 2014-06-03
- 项目状态:已结题
- 来源:
- 关键词:Antiviral AgentsAntiviral ResponseAttenuatedBlocking AntibodiesBloodCD4 Positive T LymphocytesCell MaturationCellsDataDendritic CellsDendritic cell activationDevelopmentDioxygenasesDisease ProgressionEndocytosisEnzymesEventGenerationsGenomicsHIVHIV InfectionsHIV-1HumanIL2RA geneITGAX geneImmuneImmune responseImmune systemImmunityInfectionInfection ControlInflammatoryInterferon Type IInterventionKynurenineLaboratoriesLigationLinkLymphoid TissueMediatingMediator of activation proteinModelingMolecularMonitorMusMutateMyelogenousNF-kappa BPathway interactionsPhosphorylationPhosphorylation SitePlayProcessProductionPropertyRNARegulationRegulatory T-LymphocyteRestRoleSignal TransductionSiteSmall Interfering RNAT-LymphocyteTLR7 geneTestingTimeTryptophanTryptophan 2,3 DioxygenaseUp-RegulationViralViral AntigensVirusVirus DiseasesWorkadaptive immunitychemokinecytokineimmune activationimprovedin vivoindolamineinhibitor/antagonistknock-downmembermethyl tryptophanpathogenpreventresearch studyresponseviral RNA
项目摘要
ABSTRACT
Human plasmacytoid dendritic cells (pDC) constitute a rare subset of blood dendritic cells (DC), distinct from myeloid CD11c+, ¿conventional¿ DC (cDC). Through production of high levels of type I IFN in response to virus infection, pDC serve as a critical link between innate and adaptive antiviral immune responses. Recent observations from my laboratory have highlighted their particular role in the immune regulation of HIV-1 infection. pDCs, but not cDCs, undergo activation following CD4 mediated endocytosis of HIV-1 and subsequent activation of TLR7 with genomic RNA. Activated pDCs upregulate costimulatory molecules, produce pro-inflammatory cytokines and chemokines and activate immature cDCs in a bystander fashion. As a counterpoint to the induction of these anti-viral responses, HIV-activated pDCs simultaneously induce the differentiation of Tregulatory cells (Tregs) from na¿ve resting CD4+ T cells, in a TLR7 dependent manner. Treg generation requires the expression of indolamine 2,3-dioxygenase (IDO), an enzyme that catabolizes tryptophan to kynurenine, as it is reversed upon addition of the specific inhibitor 1 methyl-tryptophan. The T regs generated (¿inducible T regs¿) inhibit the proliferation of activated T cells and maturation of cDC, thereby attenuating the induction of ongoing adaptive immune responses. Thus pDCs inhibit viral replication and promote anti-viral immunity, but at the same time limit the extent of immune activation. This newly ascribed property of pDCs is especially relevant in HIV infection where control of excessive immune activation could be essential to prevent virus dissemination and progression of disease. In this application we propose to: (1) Determine the role of TLR7 and TLR9 in HIV-induced activation of IDO; (2) Elucidate the players in the noncanonical NFkB pathway for IDO expression; (3) .Examine the pDC-derived products that cause T reg generation. These studies will greatly improve our understanding of the events that follow pDC activation by HIV and potentially result in clinically applicable approaches to enhance anti-HIV immune responses in vivo.
抽象的
人浆细胞类动物树突状细胞(PDC)构成了罕见的血液树突状细胞(DC),与髓样CD11C+,常规的DC(CDC)不同。通过响应病毒感染的高水平I型IFN的产生,PDC是先天性和适应性抗病毒免疫调查的关键联系。我实验室的最新观察结果强调了它们在HIV-1感染免疫调节中的特殊作用。 CD4介导的HIV-1内吞作用以及随后用基因组RNA激活TLR7后,PDC(而不是CDC)进行活化。活化的PDC上调了共刺激分子,产生促炎性细胞因子和趋化因子,并以旁观者的方式激活未成熟的CDC。作为对这些抗病毒反应的诱导的对立,HIV激活的PDC只是以TLR7的方式诱导了从NA¿VE静止的CD4+ T细胞中的Tregulation细胞(Treg)分化。 Treg的产生需要吲哚胺2,3-二氧酶(IDO)的表达,这是一种将色氨酸分解为Kynurenine的酶,因为在添加了特定的抑制剂1甲基甲基化合物后,它会反转。产生的T条例(可诱导的T条例)抑制了活化的T细胞的增殖和CDC的成熟,从而减弱了持续的适应性免疫调查的诱导。 PDC抑制病毒复制并促进抗病毒免疫学,但同时限制了免疫学激活程度。 PDCS的新归因性质在HIV感染中尤其重要,在HIV感染中,控制过多的免疫学激活对于防止病毒传播和疾病进展至关重要。在此应用中,我们建议:(1)确定TLR7和TLR9在HIV诱导的IDO激活中的作用; (2)阐明了以IDO表达的非规范NFKB途径中的玩家; (3)。审查导致T Reg生成的PDC衍生产品。这些研究将大大提高我们对艾滋病毒PDC激活遵循PDC激活的事件的理解,并可能导致临床适用的方法,以增强体内的抗HIV免疫调查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melissa Victoria Fernandez其他文献
Melissa Victoria Fernandez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melissa Victoria Fernandez', 18)}}的其他基金
Modulating anti-HIV immunity by plasmacytoid dendritic cells
通过浆细胞样树突状细胞调节抗 HIV 免疫
- 批准号:
7916938 - 财政年份:2010
- 资助金额:
$ 2.31万 - 项目类别:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
通过浆细胞样树突状细胞调节抗 HIV 免疫
- 批准号:
8076209 - 财政年份:2010
- 资助金额:
$ 2.31万 - 项目类别:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
通过浆细胞样树突状细胞调节抗 HIV 免疫
- 批准号:
8444730 - 财政年份:2010
- 资助金额:
$ 2.31万 - 项目类别:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
通过浆细胞样树突状细胞调节抗 HIV 免疫
- 批准号:
8238390 - 财政年份:2010
- 资助金额:
$ 2.31万 - 项目类别:
相似国自然基金
基于HEV介导炎症反应与干扰素通路信号交互机制的抗病毒策略研究
- 批准号:82370610
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RNA分子SNORA31结合cGAS并调控小胶质细胞的抗病毒天然免疫反应的作用与机制研究
- 批准号:82301981
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
溶质载体SLC38A10调控抗病毒天然免疫反应的作用及分子机制
- 批准号:32370926
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
豆天蛾质型多角体病毒的分离鉴定及其抑制宿主RNAi抗病毒反应的分子机制
- 批准号:32360701
- 批准年份:2023
- 资助金额:32.00 万元
- 项目类别:地区科学基金项目
精氨酸甲基转移酶PRMT9调控RLRs介导天然免疫抗病毒反应的分子机制研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
相似海外基金
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
靶向核 HSF1 作为一种新型抗 HCMV 策略
- 批准号:
10656697 - 财政年份:2023
- 资助金额:
$ 2.31万 - 项目类别:
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 2.31万 - 项目类别:
Antiviral innate immune responses to pathogenic coronaviruses in the nasal epithelium
鼻上皮中针对致病性冠状病毒的抗病毒先天免疫反应
- 批准号:
10678393 - 财政年份:2023
- 资助金额:
$ 2.31万 - 项目类别:
Rotavirus interaction with gut intraepithelial lymphocytes
轮状病毒与肠上皮内淋巴细胞的相互作用
- 批准号:
10738962 - 财政年份:2023
- 资助金额:
$ 2.31万 - 项目类别:
Development of rotavirus-based enterotoxigenic Escherichia coli dual vaccines
基于轮状病毒的产肠毒素大肠杆菌双重疫苗的研制
- 批准号:
10741541 - 财政年份:2023
- 资助金额:
$ 2.31万 - 项目类别: